ArticleFrontiers in oncology2026
Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidermal growth factor receptor (EGFR) gene mutations play a key driving role in the development and progression of lung cancer. Currently, EGFR tyrosine kinase inhibitors (TKIs) serve as the standard first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, with the widespread use of these drugs, resistance has become increasingly prevalent, particularly with third-generation EGFR-TKIs, posing a significant bottleneck limiting survival benefits for patients. This real-world study aims to evaluate the efficacy and safety of double-dose furmonertinib in patients with advanced NSCLC who have developed resistance to prior osimertinib therapy, with the goal of offering practical insights for clinical decision-making. Methods: A retrospective analysis was conducted on 69 patients with advanced NSCLC resistant to osimertinib. The control group received platinum-based dual-agent chemotherapy, with progression leading to subsequent-line therapy. The observation group received either double-dose furmonertinib (160 mg/day, oral) or double-dose furmonertinib monotherapy in addition to the control group regimen. Results: The observation group had significantly improved disease control rate (DCR) compared with the control group (71.1% vs 41.7%, Conclusion: In patients with osimertinib-resistant advanced NSCLC, the regimen comprising double-dose furmonertinib yielded promising efficacy, accompanied by an acceptable safety profile and overall tolerable treatment-related adverse events. In patients with osimertinib-resistant advanced NSCLC and CNS metastases, double-dose furmonertinib significantly prolongs PFS and demonstrates marked local control of CNS metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.